Business Wire

Pennsylvania Convention Authority Renews ASM Global Management Contract Becoming First Venue in World Leader’s ‘Premier Package’ Convention Center Expansion

24.8.2023 23:46:00 EEST | Business Wire | Press release

Share

The Pennsylvania Convention Center Authority (PCCA) board of directors has approved a five-year contract renewal for ASM Global as its venue management company with the convention center poised as the launch location for a dramatic series of innovations in ASM Global’s convention and conference portfolio — the largest in North America and worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230824372126/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Photo courtesy of ASM Global.

The new agreement will commence on Dec. 1, 2023, for five years, through Nov. 30, 2028, with the international entertainment leader planning to bring many of its most innovative designs to a leading group of convention centers beginning with PCCA. It will be the first in a program creating unique environments such as immersive LED moments, speed-action offerings to accelerate business strategies, elevated VIP lounges and quiet spaces for business connectivity.

“We are thrilled to announce the continued partnership between the Pennsylvania Convention Center Authority and ASM Global as the venue-management provider for the Pennsylvania Convention Center,” said David A. Nasatir, Esq., chair of the board, PCCA. “For 10 years, ASM Global has been a valued collaborator and, because of their outstanding contributions, has elevated the Pennsylvania Convention Center to world-class status.”

In 2013 the PCCA first made the decision to privatize management of the center with an initial contract being awarded to SMG, which was subsequently rebranded to ASM Global following the 2019 merger of AEG Facilities and SMG. The merger created a venue management powerhouse that spans five continents, 14 countries and more than 350 of the world’s most prestigious arenas, stadiums, theaters and convention centers and has positioned ASM Global as the world’s preeminent venue-management and live-experiences company.

“The ASM Global team at the Pennsylvania Convention Center is, without exception, the finest in the industry,” said John J. McNichol, president and CEO, PCCA. “Their innovative leadership and commitment to delivering an unmatched customer experience have positioned the center, globally, as an industry trailblazer and venue of choice, and we look forward to continuing our collaboration as we take the Pennsylvania Convention Center to the next level.”

Under the management of ASM Global, the Pennsylvania Convention Center has already implemented several cutting-edge and industry-changing initiatives such as the 2014 execution of the Customer Satisfaction Agreement, a document that guides the relationship between the center and the labor unions that work at the facility with the goal of providing a more productive, customer-centric and cost-effective worksite for guests and the ASM Global Acts program, under which the center has successfully executed a robust sustainability and social impact plan.

Dan Hoffend, ASM Global executive vice president, convention centers, said, “We’re excited to begin the next chapter for the convention universe beginning with the Pennsylvania Convention Center. This includes sustainability features that create substantial movement toward carbon neutral; new Flex-space exhibit halls that can adapt to the needs of our diverse attendees; and LED walls that provide sponsorship, wayfinding and entertainment.

“We’re bringing our proven best features from our stadiums and arenas directly to our convention centers to create a premium line of facilities like no other in the industry. Our attendees require entertainment as a part of their business paradigm. We are changing the industry by creating a unique environment for all of our guests,” Hoffend said.

PCC’s ASM Global general manager, Tony Hodgins, said, “We thank the PCCA for their continued trust in our ASM Global team and for their unwavering support over the years. Our team at the center remains focused on our goal of providing a first-class customer experience to all our guests, and we are honored to be able to continue working with our key partners to showcase all that Philadelphia and the Pennsylvania Convention Center have to offer.”

For more information on the Pennsylvania Convention Center community-engagement and outreach initiatives, visit paconvention.com.

About Pennsylvania Convention Center

Pennsylvania Convention Center is located in Center City Philadelphia at the heart of the city's many cultural offerings and world-class dining and entertainment scene. Managed by ASM Global, the center is the 14th largest facility in the nation and features one of the largest exhibit spaces and ballrooms in the Northeastern U.S. The meetings, conventions, trade shows and other events hosted by the center attract attendees from across the country and around the world to Philadelphia, making the facility the largest economic driver of the region’s hospitality industry. For more information, visit paconvention.com.

About ASM Global

ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management, delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Follow us on Facebook, Instagram, LinkedIn and Twitter. For more information, please visit asmglobal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
818-264-6812

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye